Prevention of Bleeding Complications in Neonates With Liver Failure Undergoing Surgery Using Recombinant Factor VIIa

Area of Science:

• Hepatology
• Hematology
• Pediatric Surgery

Background:

• Liver failure frequently causes coagulopathy, increasing bleeding risks during procedures like liver biopsy.
• Standard treatments such as fresh frozen plasma (FFP) and prothrombin complex concentrates (PCC) have limitations, including volume intolerance, DIC risk, and viral transmission.
• Recombinant factor VIIa (rFVIIa) is a novel therapy for hemophiliacs with inhibitors and bleeding.

Purpose of the Study:

• To evaluate the efficacy of rFVIIa in preventing bleeding complications in neonates with liver failure undergoing liver biopsy and central venous catheter (CVC) placement.
• To assess rFVIIa as a safer alternative to FFP and PCC in this high-risk pediatric population.

Main Methods:

• Three neonates with liver failure and coagulopathy underwent liver biopsy and CVC placement.
• rFVIIa was administered pre-operatively to prevent bleeding complications.
• Patients had prior mild gastrointestinal bleeding unresponsive to FFP and cryoprecipitate.

Main Results:

• None of the three neonates experienced bleeding complications post-procedure.
• rFVIIa administration was associated with successful surgical outcomes.
• The therapy was chosen over PCC due to targeted factor VII activity and reduced risks of DIC and viral transmission.

Conclusions:

• rFVIIa is a valuable therapeutic option for preventing bleeding in neonates with liver failure undergoing invasive procedures.
• The use of rFVIIa demonstrated utility in managing coagulopathy associated with liver failure.
• rFVIIa offers a promising alternative to traditional hemostatic agents in high-risk pediatric surgical patients.